PTHS
Pelthos TherapeuticsยทAMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PTHS
Pelthos Therapeutics Inc.
A biopharmaceutical company dedicated to developing drugs for the treatment of infectious soft warts
Biological Technology
03/19/2021
02/16/2024
American Stock Exchange
4
12-31
Common stock
4400 Route 9 South, Suite 1000, Freehold, NJ 07728
--
Pelthos Therapeutics Inc., a Nevada company incorporated on March 19, 2021. The company is a clinical-stage biotechnology company focused on developing and commercializing new therapies for pain relief. The company's clinical focus is selectively targeting sodium ion channels, known as "NaV 1.7," as well as other receptors in the NaV family. NaV 1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with some kind of hereditary NaV 1.7 regulation consistently show pathology of not feeling pain.
Company Financials
EPS
PTHS has released its 2025 Q3 earnings. EPS was reported at -5.3, versus the expected -0.67, missing expectations. The chart below visualizes how PTHS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PTHS has released its 2025 Q3 earnings report, with revenue of 7.41M, reflecting a YoY change of NaN%, and net profit of -16.24M, showing a YoY change of -857.99%. The Sankey diagram below clearly presents PTHS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
